(AOF) – Amgen today announced the completion of its acquisition of Horizon Therapeutics plc for $116.50 per share in cash, representing a transaction of approximately $27.8 billion. The American group announced the acquisition in mid-December 2022: the American Federal Trade Commission (FTC) attacked the project for abuse of dominant position and then suspended its challenge.